Navigation Links
Blue Door Pharma and Global Energy Markets Strike Global Export Agreement for Meningitis Vaccine and Pharmaceuticals
Date:1/11/2013

Rockville, MD (PRWEB) January 11, 2013

Blue Door Pharmacies, LLC (T/A Blue Door Pharma) announces it has executed a five year, exclusive joint partnership with Global Energy Markets, LLC for the sale and global distribution of pharmaceuticals and a low cost tetravalent meningitis vaccine. Operating under the joint partnership name BlueGem Global, the companies are in negotiations with organizations in Algeria, the Dominican Republic, Ghana, Indonesia and Iran.

“Global Energy Markets needed Blue Door Pharma’s expertise, and they needed ours,” said Global Energy Markets President and CEO, Sina Soumekhian, “For years our clients have asked for pharmaceutical access, and with this partnership we can provide it. Plus, we believe the low cost meningitis vaccine we provide will prove to be highly desirable in our target markets.”

Global Energy Markets has a broad network of international contacts and a license issued by the U.S. Department of Treasury, Office of Foreign Assets Control (OFAC), allowing them to export items to countries under US sanction. “It is a strong marriage of skills, expertise and regulatory licensing on both sides of the equation,” said Dr. Sheila Alizadeh, Founder and CEO of Blue Door Pharma.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10310124.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related medicine news :

1. FDA, States Weigh Pharmacy Regulation in Wake of Meningitis Outbreak
2. ShopPharmacyCounter.com Unveils PhenObestin 37.5 to Offset Obesity Effectively
3. Pharmacy researcher finds most popular weight-loss drug strongly alters other drug therapies
4. Devalued and distrusted: Can the pharmaceutical industry restore its broken image?
5. Women’s Excellence in Bladder Control Partners with University Compounding Pharmacy in Troy, MI to Help Women with Chronic Pelvic Pain Conditions
6. Report finds Big Pharma is doing more for access to medicine in developing countries
7. Treating cocaine dependence: A promising new pharmacotherapy
8. UBC professor wins Canadas top pharmaceutical research award
9. Compounding Pharmacists Oppose Greater U.S. Oversight
10. Owner of Meningitis-Linked Pharmacy Declines to Testify Before Congress
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... PITTSBURGH...An inventor, from Richmond Hill, ... charts in hospitals and medical facilities, so he invented the COMPLETE PATIENT CHART. , ... charts. In doing so, it offers an improved alternative to paper charts and clipboards. ...
(Date:9/25/2017)... Pa. (PRWEB) , ... September ... ... provider of specialized science and technology-enabled services supporting clinical research, today announces ... topics addressing key aspects of the drug development lifecycle at upcoming industry ...
(Date:9/25/2017)... , ... September 25, 2017 , ... Earlypicker is expanding ... a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping the nation. ... company that’s already well-known for the great offerings that allow Koreans everywhere to look ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Majestic Unicorn”: a poignant book that ... Unicorn” is the creation of published author, Dayna Chantel, an artist and a writer. ... wide to march aboard the cypress ark-vessel. Male and female, no matter what species, ...
(Date:9/25/2017)... , ... September 25, 2017 , ... Emerald Ash Borers kill Ash trees ... be seen throughout the Philadelphia region. A video by Rob Nagy, ISA Certified Arborist ... Ash trees. While several are dead or showing signs of decline from Emerald Ash ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
(Date:9/5/2017)...  Xyntek Inc. has announced another milestone in their continued growth and success ... the growing demands of customer engagements regionally.  ... new Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, ... Xyntek's recently opened ... ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
Breaking Medicine Technology: